Aptamer Selection Technology and Recent Advances
By M. Blind, M. Blank. Molecular Therapy: Nucleic Acids, 2015
305 citations recorded by the source corpus.
Over the last decade, aptamers have begun to find their way from basic research to diverse commercial applications. The development of diagnostics is even more widespread than clinical applications because aptamers do not have to be extensively modified to enhance their in vivo stability and pharmacokinetics in diagnostic assays. The increasing attention has propelled the technical progress of the in vitro selection technology (SELEX) to enhance the efficiency of developing aptamers for commercially interesting targets. This review highlights recent progress in the technical steps of a SELEX experiment with a focus on high-throughput next-generation sequencing and bioinformatics. Achievements have been made in the optimization of aptamer libraries, separation schemes, amplification of the selected libraries and the identification of aptamer sequences from enriched libraries.
Subfields: Biomedical Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/35c1feef4bca8e07285e2b6fc33ef4738aa4238d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Leon M Larcher
- Changying Chen
- R. Barrero
- R. Veedu
- Tao Wang
Citations in the corpus
- Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development. (2019, background): “various leading groups such as Sullenger's group at Duke University (2′Fluoro, 2'-O-methyl and 2'-OH nucleosides) (Blind and Blank, 2015), AM Biotech at UT Houston (Phosphorodithioate, 2'-O-methyl and Xmodified dU) (Lokesh et al.”